| Code | 24663 | ||||||||||
| MA number | 16/0209/18-S | ||||||||||
| Product Form: | tbl 100x5 mg (liek.HDPE) | ||||||||||
| MA Status: | D - Marketing Authorisation valid for an unlimited period | ||||||||||
| Type of procedure: | National | ||||||||||
| MAH, country: | Orion Corporation, Finland | ||||||||||
| Therapeutic Class: | 16 - ANTICOAGULANTIA (FIBRINOLYTICA, ANTIFIBRINOL.) | ||||||||||
| ATC: |
|
||||||||||
| Shelf life: | 36 | ||||||||||
| Container: | container HDPE | ||||||||||
| Route of admin.: | Oral use |
| Prescription Status: | Medicinal product subject to medical prescription. |
| Legal basis: | Article 10a well-established use application |
| MA issued: | 06.03.1989 |
| Pediatric posology: | Yes |
| PIL: |
PIL_WARFARIN ORION 3 mg_5 mg_02.2025.pdf
|
| SPC: |
SPC_WARFARIN ORION 3 mg_5 mg_02.2025.pdf
|
| Safety feature | Yes |
| Data update: | 03.07.2018 |
